expect solid quarter driven continu execut believ
opportun upsid light recent downturn investor sentiment
nbi under-perform ytd vs ytd driven larg part
declin end end view investor remain concern drug
price especi elect growth broader macroeconom issu
howev believ continu commerci clinic execut could contribut upsid
evid fundament strength could improv investor sentiment toward
recal beat across board revenu ep weve seen recent
fundament chang industri suggest soft beyond season compani
specif legal overhang mostli resolv except on-going
challeng biogen tecfidera ip decis ipr challeng expect
discuss view sector go earn host call
biotech colleagu friday octob et dial-in us ou
increas posit sector somewhat off-set increas
regulatori scrutini acquisit array allergan otezla alder help
enhanc investor sentiment continu support valuat howev
allergan receiv second request ftc rais concern biotech come
increas regulatori scrutini recal bristol/celgen subject second request
lead delay closur transact ultim result divestitur otezla
overal believ limit data point support conclus face
greater regulatori hurdl note smaller continu happen healthi pace
vertex neurocrin well pois ahead quarter vertex project higher
ep con con rev cs vs continu
believ guidanc conserv beatabl neurocrin could beat ingrezza rev
cs though note ingrezza sale seen histor
soft due season beat may provid tougher qoq comparison
quarter could mix consensu expect
revenu cs vs con ep vs weve seen sign
resili base busi led enbrel may off-set under-perform
repatha neulasta increas due advanc pipelin season
could face challeng quarter project lower revenu
compar consensu seen evid zolgensma
use sma recal report weaker spinraza sale weak could
continu new incid patient receiv zolgensma might previous start
spinraza load phase spinraza first year make expens year
treatment patient receiv dose drug eros incid market could
lower averag revenu per patient time
weve made chang target price estim detail herein
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek
busi compani cover research report result investor awar firm may conflict
interest could affect object report investor consid report singl factor make
press releas thursday pm et call follow day
major surpris unlik go expect continu base busi resili
clariti kra biosimilar base busi resili
expect led enbrel prolia xgeva though could see weak neulasta
given recent trend slow repatha sale weve lower outer-year estim
enbrel cs vs con repatha cs vs con
continu expect slower enbrel eros consensu given recent remov
litig overhang though moder assumpt expect
enbrel core compon outperform thesi meet consensu expect
beyond repatha would acceler growth unlik
view given commerci challeng space loom competit
reiter outperform rate lower tp follow
model adjust
look biosimilar franchis start see posit result amgen
effort diversifi revenu base busi strong uptak europ
kanjinti herceptin biosimilar amjevita humira expect continu us
believ biosimilar could contribut revenu upcom month recent
mvasi avastin kanjinti launch potenti fda approv month
defens moat context drug price legisl
focu point call expect detail around monotherapi trial
updat regard us biosimilar launch includ potenti abp
approv listen detail regard compani presenc
decemb also interest updat regard otezla deal
model chang valuat weve increas sale reflect greater base
busi resili reduc outer-year enbrel repatha estim
forecast non-gaap ep target price
deriv dcf analysi use wacc termin growth
risk tp rate clinic development commerci regulatori
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
inc biotechnolog compani engag discoveri
develop manufactur market human therapeut
blue sky scenario assum tvgr better current
assumpt base-busi greater
current forecast assum greater expect growth
biosimilar franchis slower expect declin base
busi also assum posit data readout pipelin asset
regulatori approv abp abp
base busi sale poorer growth profil biosimilar
busi key pipelin asset assum slower expect
growth biosimilar franchis regulatori headwind drug
approv ip litig scenario assum lose patent
litig soliri enbrel also assum neg data readout
pipelin asset
 close
model chang weve increas sale reflect greater base busi resili
given better expect perform enbrel nplate parsabiv make smaller
adjust product reflect current sale trajectori weve lower outer-year
estim enbrel cs vs con repatha cs vs
con continu expect slower enbrel eros consensu given recent
remov litig overhang though moder assumpt
expect enbrel core compon outperform thesi forecast non-
gaap ep target price deriv dcf
analysi use wacc termin growth
valuat target price deriv dcf analysi use wacc
termin growth forecast cash flow account known expect
product launch patent expir competit threat current commerci
portfolio pipelin beyond forecast period appli termin growth rate
termin cash flow believ eros base busi off-set
growth elsewher portfolio continu invest bd
success replac revenu faster rate eros long-term
contribut biosimilar investig oncolog asset tezepelumab
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv investig product
commerci sale
expect continu weak absent larg scale pipelin progress
consensu ep revenu consist under-perform thesi
project ep versu consensu revenu
compar averag ms sale cs vs
consensu base tecfidera ip litig overhang increas competit
continu believ potenti ms eros fulli appreci ms
franchis also see vumer drive signific growth drug larg
next gener version tecfidera spinraza franchis expect drug
meet expect see long-term headwind ahead approv
zolgensma potenti approv risdiplam agre spinraza
best long-term safeti record base recent nurtur studi howev
recent risdiplam data world muscl societi continu look competit spinraza
given oral dose believ risdiplam prefer spinraza intrathec
inject assum data least non-inferior safe continu believ
eros spinraza underappreci consensu
focus pipelin continu expect modest opportun al
stroke pain note possess pipelin asset could
address larg unmet popul asset earli stage assign valu
includ psp parkinson diseas system lupu
erythematosu feel increasingli necessari counteract erod ms
sma franchis
focu point call expect manag focu recent posit result
nurtur studi spinraza sma infant updat
advanc spinraza expect addit color pipelin asset psp sle
state compani expect updat result near-term look
updat capit alloc strategi current priorit short-term share buyback
model chang weve increas estim near-term tysabri sale light recent
resili off-set partial lower benepali sale forecast non-gaap ep
make chang tp rate
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc biopharmaceut compani engag
discov develop deliv therapi neurolog
experi greater expect degre eros
competit eros occur partial off-set sale
vumer spinraza remain standard care sma risdiplam
zolgensma either fail clinic take meaning share
share repurchas lead meaning accret constant
grey scenario assum ms franchis declin greater
expect rate new therapi take greater expect share
near-term zolgensma captur major new incid
sma market long-term spinraza lose share risdiplam
preval sma market capit deploy strategi fail
gener meaning earn growth share experi even
greater degre multipl compress
 close
model chang weve increas estim near-term tysabri sale light recent
resili off-set partial lower benepali sale tysabri sale stronger expect
expect steep declin growth benepali slower
expect reduc assumpt reflect sale trajectori asset
inc ms product biosimilar revenu incom dilut charl martineau pm univers toronto octob
expect new ceo strategi take time developslightli ep
project non-gaap ep vs con believ hiv franchis
meet expect due continu uptak biktarvi believ best-in-class
also believ recent approv descovi prep help mitig impact
truvada gener data support use prep patient prefer taf-bas
regimen limit model descovi prep despit posit
outlook hiv franchis believ continu hiv/prep alon unlik
drive meaning upsid market well-understood long-term franchis
expect declin upon backdrop remain cautious optimist
day strategi understand may take month matur
last quarter saw signific chang manag across compani includ
new ceo christi shaw kite recent gilead appoint andrew dickinson cfo
replac gilead veteran robin washington plan retir although
surpris gilead chose promot within compani given oday recent trend
hire extern key leadership role anticip major strateg chang
next quarter expect manag chang take time impact
look pipelin expect nda file filgotinib us per
discuss manag regulatori submiss accept europ
japan believ execut filgotinib year step right direct reduc
depend hiv franchis yet need see larger scale continu
execut around long-term growth trajectori busi improv
focu point call expect updat regard descovi prep
commerci updat biktarvi also look us regulatori submiss
timelin filgotinib along like approv timefram eventu launch
interest hear addit detail day strateg vision clinic area interest
model chang weve increas oper expens assumpt reflect recent
perform previous model save relat nash program come
fruition forecast non-gaap ep make
chang tp rate
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc biopharmaceut compani engag
research develop commerci medicin
area infecti diseas oncolog immunolog area
sky scenario model probabl success
yescarta expans well filgotinib also assum success
mid-stag nash asset exclud selonsertib maintain base
case third line yescarta hiv hcv sale
grey sky scenario model car-t platform
success beyond dlbcl filgotinib program delay fail
meet base-cas expect nash program fail
maintain base case third line yescarta hiv hcv sale
 close
model chang weve increas oper expens assumpt reflect recent
perform previous model save relat nash program come
fruition follow disappoint result selonsertib expect reduc invest
nash remov cost reduct model pend formal discontinu
program
gilead axicabtagen franchis ex product revenu includ glpg incom cs loss incom cs dilut cs charl martineau pm univers toronto octob
slightli upbeat better-than-expect dupix launch help drive
profit sanofi collabor eylea meet expect long-term
headwind exist upbeat dupix given strong uptak
saw help drive beat sanofi collabor project
slightli higher revenu sanofi collabor vs consensu
long term continu believ dupix face competit asthma atop
dermat ad feel fulli appreci consensu weve
increas cost throughout forecast reflect recent perform guidanc
reimburs declin believ regeneron increas invest un-
partner model adjust lower tp
reiter neutral rate
eylea franchis expect drug meet expect believ long-
term project may high given recent approv novarti beovu
brolucizumab could first signific challeng eylea leadership sinc
launch channel check physician state beovu advantag dri
eye import differenti could support use furthermor eylea
could risk drug price reform take place given eylea reimburs
one top drug reimburs medicar part overal continu
believ expect key revenu gener line-item high
focu point call look discuss around recent approv
competitor beovu wamd could potenti impact eylea sale also
expect hear detail dupix expans eu addit hope hear
detail regard halt palm ebola clinic trial follow step regn-
given data show superior zmap
model chang valuat weve increas cost throughout forecast
forecast non-gaap ep target price
deriv dcf analysi use wacc termin growth
risk tp rate clinic development commerci regulatori
valuat metric
number share
 close
model chang weve increas cost throughout forecast previous expect
modest declin spend reimburs declin given regeneron recent
highlight unpartn program expect unreimburs increas
maintain current level spend percentag revenu regeneron look next
leg growth
million priorcurrentchangepriorcurrentchangepriorcurrentchangeeylea collabor mab revenu reimburs reimburs loss incom dilut charl martineau pm univers toronto octob
valuat target price deriv dcf analysi use wacc
termin growth forecast cash flow account known
expect product launch patent expir competit threat current
commerci portfolio pipelin beyond forecast period appli termin
growth rate termin cash flow believ eros base busi
off-set growth elsewher portfolio eylea market leader across mani indic
dupix similar best-in-class potenti compani uniqu collabor approach
develop commerci key asset allow benefit
special expertis partner retain access portion blockbust upsid
potenti benefit somewhat off-set increas risk relianc
intern partner reduc control ex-u commerci strategi spend
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv regneron investig
product commerci sale
price
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc engag discoveri invent
develop manufactur commerci medicin
treatment seriou diseas
blue sky scenario assum better expect sale
dupix praluent kevzara libtayo eylea
grey sky scenario assum lower forecast
competit across core busi eylea dupix praluent
libtayo kevzara
 close
vertex remain one top pick leader cf space low
competit pipelin optionalityw ahead earn revenu
despit manag rais revenu guidanc post remain confid
cf base busi continu expand potenti outperform guidanc
cs ep consensu consist outperform thesi forecast
higher revenu consensu vs recal vertex receiv
approv septemb immedi sell orkambi symkevi scotland could
add increment sale given scotland agreement
hope broader uk deal could reach give vertex access
address ww cf market believ expans eu reimburs
agreement particularli uk franc may add upsid long term revenu
pipelin like option vertex antitrypsin defici
program pain program target crispr gene edit howev
note thesi predic sole upon cf-revenu therefor materi progress
pipelin could provid addit upsid base case
focu point call in-lin vertex strategi acquir earli stage asset
expect updat regard recent acquisit collabor vertex recent announc
collabor ribometrix discov develop rna-target small molecul
therapi also expect get detail vertex acquisit semma
therapeut posit type diabet space reimburs look
progress forg new reimburs agreement uk franc
pipelin await updat program crispr collabor realiz
catalyst expect
model chang lower cost reflect ytd spend guidanc
weve moder launch year sale estim tripl remain ahead
consensu expect degre patient switch believ high
unmet need drive launch sale ahead consensu project non-gaap
ep make chang target price rate
valuat metric
number share
 close
vertex engag develop commerci therapeut
rare diseas includ main franchis cystic fibrosi
scenario assum dcf valu share
cut sg respect also assum
regulatori approv tripl combin us
ou assum posit proof-of-concept data next gener cf
asset also assum posit data updat
pipelin asset gene-edit system
grey sky scenario model less credit triplet
lower probabl success reflect increas risk
compani face meaning setback
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
model chang lower cost reflect ytd spend guidanc
get closer launch tripl weve refin assumpt reflect launch-year
penetr newli address age popul moder sale estim
first year remain ahead consensu expect degre patient
switch believ high unmet need drive first-year sale ahead consensu
vertex residu tripl combin revenu loss incom cs dilut cs charl martineau pm univers toronto octob
statu quo head jakafi revenu expect
meet expect revenu driven mainli jakafi cs vs
believ jakafi remain market leader myelofibrosi mf
polycythemia vera pv best-in-class drug view expand indic
jakafi graft-versus-host diseas unlik provid signific revenu longer term
see near-term threat franchis although upsid jakafi
gener well appreci street per discuss manag issu
season unusu circumst unlik rest market
portfolio believ iclusig olumi royalti meet expect
look toward pipelin saw signific progress topic ruxolitinib
pemigatinib like asset believ could gain traction
market success howev market asset modest look pemigatinib
cholangiocarcinoma estim market patient peak sale
data present esmo compel could read
larger bladder cancer indic peak sale
could provid better diversif jakafi revenu highlight pemigatinib
compet directli js balversa uc posit topic ruxolitinib data
recent eadv vitiligo demonstr durabl week continu
safeti expect modest revenu vitiligo although drug
use atop dermat ad could provid greater revenu face
increas competit overal believ execut pipelin strategi
sever asset could reduc relianc jakafi
focu point call look updat pemigatinib bladder cancer along
specifics/ time around regulatori submiss cholangiocarcinoma
continu wait detail surround commerci strategi topic ruxolitinib
could commerci intern out-licens spun
model chang greater clariti time expect topic ruxolitinib
launch submiss late weve push forward revenu
model accordingli make chang tp rate
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
incyt corp biopharmaceut compani engag
discoveri develop commerci proprietari therapeut
oncolog hematolog dermatolog
blue sky upsid case valuat base fda
approv itacitinib steroid-nav gvhd pemigatinib
cholangiocarcinoma within next month also assum better
expect jakafi revenu
grey sky downsid valuat assum fda
approv pemigatinib itacitinib grey sky also assum neg data
readout pemigatinib urotheli cancer also assum jakafi
revenu lower expect
 close
model chang recent convers compani expect topic ruxolitinib
launch submiss late weve push forward revenu model
accordingli make chang tp rate regulatori path forward
becom clearer recent updat program previous anticip late
incyt corpor million priorcurrentchangepriorcurrentchangepriorcurrentchangejakafi ruxolitinib sale ruxolitinib ad ruxolitinib royalti revenu loss incom cs dilut cs charl martineau pm univers toronto octob
expect overal solid perform neurocrin anticip
soft ingrezza due season remain posit ingrezza long-term
potenti forecast peak sale howev project slight ingrezza
beat cs vs consensu project slower growth due
season issu believ ingrezza remain best-in-class treatment tardiv
dyskinesia td key driver outperform thesi neurocrin continu
believ ingrezza achiev meaning uptak despit competit teva austedo
undersold ingrezza expect per factset
addit remain posit orilissa second line therapi endometriosi
em uterin fibroid uf expect increment valu indic
come year recal orilissa alreadi commerci avail em
expect launch uf project unadjust royalti
pipelin posit opicapon levodopa extend parkinson diseas
pd improv efficaci toler side effect dose conveni differenti
could drive prefer competitor comt inhibitor space
view recal fda accept opicapon nda juli expect
commerci launch unadjust sale lastli remain
encourag neurocrin pipelin includ congenit adren hyperplasia
program voyag gene therapi collabor given continu
confid nbix base busi pipelin upsid reiter outperform
thesi tp
focu point call given import ingrezza believ consider time
call explain season issu project long-term growth
franchis expect manag discuss potenti launch time detail
opicapon uf also look updat regard program voyag
valuat metric
number share
 close
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
inc commercial-stag biopharmaceut
compani discov develop intend commerci drug
treatment neurolog endocrin relat diseas
blue sky valuat base fda approv elagolix
uterin fibroid opicapon parkinson diseas also assum
posit pivot congenit adren hyperplasia
posit data gene therapi asset vy-aadc
voyag transact furthermor assum better expect
growth ingrezza orilissa endometriosi
grey sky valuat assum fda approv elagolix
uterin fibroid opicapon parkinson diseas assum
neg top-line pivot congenit adren hyperplasia
grey sky also assum lower expect revenu ingrezza
 close
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
